These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 23643157)

  • 1. Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS).
    Sato T; Ito K; Tamada T; Kanki A; Watanabe S; Nishimura H; Tanimoto D; Higashi H; Yamamoto A
    Magn Reson Imaging; 2013 Oct; 31(8):1412-7. PubMed ID: 23643157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
    Sieber MA; Pietsch H; Walter J; Haider W; Frenzel T; Weinmann HJ
    Invest Radiol; 2008 Jan; 43(1):65-75. PubMed ID: 18097279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats.
    Clément O; Mühler A; Vexler V; Berthezène Y; Brasch RC
    Invest Radiol; 1992 Aug; 27(8):612-9. PubMed ID: 1428739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NSF evaluation of gadolinium biodistribution in renally impaired rats: Using novel metabolic Gd2O3 nanoparticles coated with β-cyclodextrin (Gd2O3@PCD) in MR molecular imaging.
    Ashouri H; Riyahi Alam N; Khoobi M; Haghgoo S; Rasouli Z; Gholami M
    Magn Reson Imaging; 2024 Apr; 107():120-129. PubMed ID: 38215955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging.
    Schuhmann-Giampieri G; Frenzel T; Schmitt-Willich H
    Arzneimittelforschung; 1993 Aug; 43(8):927-31. PubMed ID: 8216456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy.
    White GW; Gibby WA; Tweedle MF
    Invest Radiol; 2006 Mar; 41(3):272-8. PubMed ID: 16481910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging.
    Tsuda N; Okada M; Murakami T
    Invest Radiol; 2007 Apr; 42(4):242-7. PubMed ID: 17351431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3-5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis.
    Marckmann P; Nielsen AH; Sloth JJ
    Nephrol Dial Transplant; 2008 Oct; 23(10):3280-2. PubMed ID: 18436563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence.
    Reimer P; Rummeny EJ; Shamsi K; Balzer T; Daldrup HE; Tombach B; Hesse T; Berns T; Peters PE
    Radiology; 1996 Apr; 199(1):177-83. PubMed ID: 8633143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
    Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
    Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phantom and animal studies of a new hepatobiliary agent for MR imaging: comparison of Gd-DTPA-DeA with Gd-EOB-DTPA.
    Yoshikawa K; Inoue Y; Akahane M; Shimada M; Itoh S; Seno A; Hayashi S
    J Magn Reson Imaging; 2003 Aug; 18(2):204-9. PubMed ID: 12884333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Renal enhancement and excretion of the hepatobiliary contrast agent Gd-EOB-DTPA].
    Zangos S; Hammerstingl R; Mack MG; Straub R; Engelmann K; Eichler K; Balzer T; Vogl TJ
    Rofo; 2001 Nov; 173(11):1034-40. PubMed ID: 11704914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA.
    Runge VM
    J Comput Assist Tomogr; 1998; 22(4):643-50. PubMed ID: 9676461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice.
    Wadas TJ; Sherman CD; Miner JH; Duncan JR; Anderson CJ
    Magn Reson Med; 2010 Nov; 64(5):1274-80. PubMed ID: 20648683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver MRI with contrast enhancement.
    Runge VM
    Crit Rev Diagn Imaging; 1997 Jun; 38(3):207-30. PubMed ID: 9226107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis.
    Abraham JL; Thakral C
    Eur J Radiol; 2008 May; 66(2):200-7. PubMed ID: 18374532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging.
    Chrysochou C; Power A; Shurrab AE; Husain S; Moser S; Lay J; Salama AD; Kalra PA
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):484-9. PubMed ID: 20093350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relaxivity of Gd-EOB-DTPA and Gd-DTPA in liver and kidney of the Wistar rat.
    Shuter B; Tofts PS; Wang SC; Pope JM
    Magn Reson Imaging; 1996; 14(3):243-53. PubMed ID: 8725190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy.
    Gibby WA; Gibby KA; Gibby WA
    Invest Radiol; 2004 Mar; 39(3):138-42. PubMed ID: 15076005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.